Introduction
Although bone is one of the few organs in the body that can spontaneously heal and restore function without scarring, it has been recognized that repair is not always satisfactory. Bone healing is inadequate in critical-sized defects and may also be impaired due to aging, diabetes, nicotine abuse or compromised vascularity; non-union following fracture occurs in 5-10% of cases. 1 Healing has been greatly improved by the introduction of autografting, which has become the gold standard of repair for osseous defects. However, this exposes patients to additional surgical procedures with their associated morbidity, and the amounts of bone available for autografting are limited. [2] [3] [4] Since the landmark study of Urist 5 in 1965, which showed the osteoinductive capacity of demineralized bone matrix, osteoinductive cytokines have been under intense investigation. This has been driven by the desire to produce a safe and effective substitute for autologous bone graft. The most heavily studied osteoinductive cytokines are bone morphogenetic protein 2 (BMP-2) and BMP-7 (BMP-7 is also called osteogenic protein-1). 6, 7 The FDA have recently approved recombinant, human BMP-2 and BMP-7 for restricted clinical use. Yet while the findings in animal studies have been impressive, clinical trials, although promising, have not achieved comparable results. [8] [9] [10] Reasons for this are unclear but may relate to the need for improved methods of growth factor delivery. In two clinical trials, large doses of BMP were required to induce adequate bone repair, suggesting that the mode of BMP delivery still requires further optimization. 8, 9 It is not known what side effects are associated with such high doses of BMP. Therefore, there is concern that a single exposure to an exogenous growth factor may not induce an adequate osteogenic signal in many clinical situations, particularly in cases where there is compromised bone stock and vascularity. Delivery needs to be sustained, because these factors have exceedingly short biological half-lives, usually of the order of minutes or hours, rather than the days or weeks needed to stimulate a complete osteogenic response. Gene transfer has the potential to provide more sustained protein production and to deliver protein in a more physiologic manner than is possible by direct delivery of recombinant proteins. 11, 12 In vivo gene delivery is a relatively simple technique, which favors inexpensive clinical application. In terms of orthopedic applications involving tissue repair, recombinant adenoviruses possess several advantages including their ease of preparation and ability to infect cells in situ with high transduction efficiency, leading to gene expression for several weeks, which may be ideal for bone healing. 13 When using an adenoviral vector there is concern about the development of an immune response, which can inhibit transgene expression. [14] [15] [16] This may limit the utility of these vectors for bone healing; osteogenesis following intramuscular injection of recombinant adenovirus-carrying osteogenic genes is typically weak in immunocompetent animals.
However, the extent of the immune response against adenoviral vectors seems to be modified by the route of administration. 17 Development of adenovirus-specific neutralizing antibodies generally hinders the repeated administration of the vector, 16, 18 although effective repeated intramuscular administration of adenovirus in sensitized animals has been reported. 19 We have demonstrated, that direct intraosseous administration of adenoviral vector encoding BMP-2 heals critical-sized defects (1.3 cm) in the femurs of immunocompetent rabbits. 20 This observation has been repeated recently in immunocompetent rats and Bertone et al. 21 accelerated the healing of a tibial defect in rabbits by the direct injection of Ad.BMP-6. 22 Moreover, adenoviral vectors encoding bone morphogenetic protein-2 (Ad.BMP-2) stimulated bony ingrowth into tendon grafts for the replacement of anterior cruciate ligaments in immunocompetent rabbits. 23 Intraosseous administration of recombinant adenovirus vectors may thus achieve useful levels of bone deposition in immunocompetent animals. The ability of BMP gene transfer to improve bone healing in larger animal models such as dogs or sheep has not been evaluated, even though the FDA recommend supplementary testing in large animal model. 24 The current investigation used a sheep model to determine the efficacy of local adenoviral gene transfer including duration of gene expression and systemic distribution using the marker gene luciferase. Once evidence of efficient gene transfer was documented, bone defect healing after local application of Ad.BMP-2 into an iliac crest defect and fracture repair at midshaft tibial osteotomy were evaluated by analyzing the ingrowth of bone into the defect and callus width including mechanical properties. A potential systemic effect was evaluated by analyzing the injected, as well as the contralateral, iliac crest defect.
Results
A cylindrical defect in the iliac crest together with a midshaft tibial osteotomy were surgically created in white mountain sheep. The first part of this study investigated transgene expression using an adenoviral vector coding for the marker gene luciferase. All animals tolerated the surgical procedure and the administration of vectors without clinical side effects. The body weight was recorded weekly and in all animals the body weight was stable and changed o4% (data not shown).
Gene expression
For testing transgene expression, luciferase activity, normalized to the amount of protein in the sample, was measured at serial time points post-infection with Ad.Luc. At the site of local application of adenoviral vector we observed high levels of luciferase activity at days 2 and 7 with subsequent decrease in the following weeks ( Figure 1 ). Low levels of luciferase were still detected at the 5-week time point, but not at 6 weeks. The transgene product was found in bone samples as well as in soft tissue and muscle samples from the site of injection at the iliac crest (Table 1) . Gene expression in tissue samples other than the injection site indicate low systemic distribution of the adenoviral vector after local application. Expression of the transgene was detected in tissue samples of distant organs in only two animals receiving a single injection of Ad.Luc (Table 1) . The normalized luciferase activity in these samples (lymph node, contralateral iliac crest, kidney, brain and thyroid gland) was more than 10 000 times lower than the activity in tissues of the corresponding injection site. No luciferase activity was found in the majority of tissue samples. 
Callus formation at tibial osteotomy
The second part of the study evaluated the effect of BMP-2 gene transfer on bone defect healing and callus formation in sheep. One animal of control group 2b had to be excluded due to implant failure. A 3 mm midshaft osteotomy was surgically created in the tibiae of white mountain sheep and the healing was monitored by radiographs, biomechanical testing and histology. The callus width in animals treated with Ad.BMP-2 did not show the steep increase of callus formation at week 3 seen in the control group (Figure 2) . At the end of the observation time a significantly larger callus width relative to baseline was observed by lateral X-ray in the control group compared to the treated group (P ¼ 0.010).
Following euthanasia the right and left tibiae of each animal were harvested and subjected to torsional testing. The data of torsional stiffness (Nm/1) and torsional strength (Nm) were evaluated ( Table 2) . No difference occurred between intact tibiae of control and treated animals for all parameters tested. The values for the osteotomized and intact tibiae of each animal were compared and the ratio (%) used for further analysis of differences between the groups. Torsional strength (P ¼ 0.046) was higher in the control group indicating weaker biomechanical properties of the newly formed bone in the Ad.BMP-2-treated animals.
Undecalcified histology confirmed that treatment with Ad.BMP-2-inhibited callus formation ( Figure 3 ) and led to callus tissue of lesser maturity. By the end of week 8 post-surgery, the osteotomized bone in the sheep was bound by hard callus with woven and lamellar trabecular bone. In contrast to the control group, bone healing in Ad.BMP-2-treated animals was characterized by smaller callus area, lesser degree of orientation of the Injection site:
Luciferase expression at distant organs indicates a low systemic distribution. Each column represent one animal killed 2-42 days after injection of the vector (+++ ¼ 410 000, ++ ¼ 1000-10 000, + ¼ 50-1000 and À ¼ o50 RLU/mg protein).
Figure 2
The increase in mineralized callus width from baseline values determined by standardized lateral X-ray (*Po0.05 for differences between the groups). 
Bone ingrowth at iliac crest defect
The ingrowth of bone into a cylindrical defect was evaluated by micro-computed tomography (CT) analysis. To determine a potential systemic effect both the injected and contralateral (untreated) iliac crest were analyzed. The formation of new bone within the defect 8 weeks after local application of Ad.BMP-2 was significantly lower compared to untreated control group (P ¼ 0.022). The contralateral defects of the treated animals showed a similar decrease of ingrowth indicating a systemic inhibition of bone formation (P ¼ 0.008) ( Figure 5 ). Following micro-CT analysis representative sections of all iliac crest samples were examined histologically confirming the lower content of mineralized tissue within the treated defects ( Figure 6 ). The defects were filled with mineralized, cartilagenous, fibrous and adipose tissue. Giemsa-eosine staining showed inflammatory cells within the defects ( Figure 7 ). The number of inflammatory cells was quantified using a computerbased image analyzer demonstrating significantly higher numbers of cells in both defects of the Ad.BMP-2-treated animals (P ¼ 0.014 and 0.10) ( Table 3 ). There was a trend for sheep in the Ad.BMP-2 group to have a higher percentage of adipose tissue within the defect. Clusters of chondroblast-like cells were found in histological sections from control animals only.
Detection of antibody against viral vector and transgene
Neutralizing antibodies against the adenoviral vector were determined by a functional assay using serum from each animal taken at serial time points (0, 2, 4 and 8 weeks). Neutralizing antibodies against the adenoviral vector type 5 were not observed in any of the samples from the control group or in samples taken prior to vector application from the treated animals. But antibodies were consistently found in all samples after surgery taken from animals treated with Ad.BMP-2. The highest dilution inhibiting in vitro transduction was 41:400 at week 2, 1:3007155 at week 4 and 1:2407 164 at week 8. Antibodies against human BMP-2 were determined using an enzyme-linked immunosorbent assay (ELISA) assay. The change of optical density in Ad.BMP-2-treated animals was higher (+0.8770.47) than control animals (À0.1270.13) (P ¼ 0.005) indicating the development of antibodies against human BMP-2. The ELISA assay was performed using different dilutions of the serum samples and identical results were obtained. The values for the osteotomized and intact tibiae of each animal were compared and the ratio (%) used for further analysis of differences between the groups (*Po0.05 for differences between Ad.BMP-2 and control). a b Figure 3 Representative callus formation in adenoviral vectors encoding bone morphogenetic protein-2 (Ad.BMP-2)-treated animal (a) and control animal (b) after 8 weeks (Giemsa-eosine stain). Note the horizontal osteotomy gap perpendicular to the cortical bone. In controls the gap is entirely filled with mature woven bone and partly lamellar bone (b). The bone healing in Ad.BMP-2-treated animals is characterized by small portions of woven bone but large areas of fibrous or cartilagenous tissues (a).
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Discussion
Previous studies by Baltzer et al. 20 and Betz et al. 22 have shown increased bone formation and healing of critical size femoral defects after direct in vivo application of adenoviral vectors coding for human BMP-2. These studies were performed in rabbits and rats, respectively. Here we report the first findings in a large animal.
The first part of the study aimed to evaluate the efficiency and duration of gene expression. Adenoviral vectors are widely used in experimental gene therapy because of their high transduction efficiency and their ability to infect cells in situ. An important limitation that has emerged in the use of adenoviruses has been loss of transgene expression. The injection of first-generation adenoviral vector typically results in a rapid decline of transgene expression in immunocompetent animals. 18, 25 Although gene expression following local application was also temporary in the present study using normal sheep, luciferase was detected for up to 5 weeks at the site of injection. Gene transfer was highly effective, resulting in high initial levels of transgene expression which, although transient, may be well match the requirements of bone healing. Adenoviral vectors are known to transduce most cells involved in bone healing, including osteoblasts, 26 fibroblast 27 and myoblasts 28 which support our finding of high luciferase levels in tissue samples from bone, fascia and muscle. Consistent with our results, the greatest expression of the transgene occurred in the musculature surrounding the injection site when using a rabbit model. 13 After adenoviral infection, transgene expression was largely confined to tissues in and around the iliac crest defect. Only weak luciferase activity was detected in various distant organs, including lymph node, kidney, brain or thyroid. This might indicate that a minor fraction of the injected adenovirus circulated systemically and infected cells distant to the injection site. The luciferase activity at distant sites was 10 000 times lower than the activity at the corresponding injection site. These observations confirm the data of Baltzer et al. 13, 20 who demonstrated that transduction of cells in a rabbit fracture model was mostly limited to the site of injection.
In the second part of the present study the iliac crest defect was chosen as a standardized bone defect model and the midshaft tibial osteotomy as an established fracture model in a sheep. 29, 30 Adenoviral vectors carrying the cDNA encoding BMP-2 were directly injected into the osseous defect and osteotomy gap during surgery. Control animals received injections of saline, and one limitation of the present study is the absence of animals receiving an intra-lesional injection of control vector. Such animals would permit us to determine whether the recombinant adenovirus alone inhibits bone formation. Studies of this type will be necessary in the future.
Bone formation was evaluated by a standardized three-dimensional method using micro-CT measurement as well as histological analysis. Callus formation was monitored by conventional X-ray and mechanical properties were tested after euthanasia. Fracture healing in this midshaft tibial osteotomy is driven by endochondral bone formation. 29, 30 However, the administration of BMP-2 may favor membranous bone formation. Thus, the callus size does not represent a favorable end point parameter and biomechanical testing is needed to a b Figure 4 Representative pictures of the osteotomy zone after 8 weeks. Arrow bars indicate the cortical ends. In Ad.BMP-treated animals (a) the osteotomy zone was mainly filled with fibrous tissue, but small areas of newly formed woven bone were present indicating an early stage of intramembraneous bone healing. In control animals (b) the gap was mainly filled with lamellar trabecular bone, but woven bone is still visible. Figure 5 Bone volume within the iliac crest defects after 8 weeks separated for the treated and contralateral untreated iliac crest (*Po0.05 for differences between adenoviral vectors encoding bone morphogenetic protein-2 (Ad.BMP-2) and control).
Ad
The results demonstrate delayed fracture healing including lesser stability in torsion following the treatment with Ad.BMP-2. In order to detect a possible systemic effect of Ad.BMP-2 after local application, cylindrical defects were created at both sides of the pelvis. The defects were treated unilaterally by application of Ad.BMP-2 and showed a significantly lesser ingrowth of cancellous bone compared to the control group. The ingrowth of bone into the untreated contralateral defect in Ad.BMP-2-treated animals was also significantly lower than the control group. Thus, this paper shows that a systemic inhibition of defect healing was seen after local intraosseous application of Ad.BMP-2 in an ovine animal model. Collectively, the results of this study show that the direct application of Ad.BMP-2 leads to a retardation in bone formation, although high amounts of the transgene product were found. This finding stands in contrast to the data obtained with small animal models 20, 22 and raises the question of how bone healing was delayed after application of Ad.BMP-2. Our data implicate immune reactions to the adenovirus vector and against a b 31 Southwood et al. 32 reported similar findings when attempting to heal infected defect fractures in rabbits with Ad.BMP-2.
Viral antigens plus those derived from the transgene probably contribute to cellular immune responses leading to the destruction of the genetically modified cells and the migration of inflammatory cells into the bone defect. 33, 34 Neutralizing antibodies were detected using a functional bioassay after the first administration of adenoviral vector. An inflammatory response following direct injection of adenoviral vector carrying osteogenic genes into muscle was previously described to be clearly present at day 3, and to gradually decrease over time, resolving by day 21. 35 The route of administration influences the immune response to viral vectors. 17, 19 We propose that the intra-osseous route of application favors a delayed inflammatory response which allows transgene expression for up to 5 weeks.
Differences in animal husbandry may explain the unexpected results in this study. Small animals like New Zealand White rabbits or Lewis rats are born and raised in standard laboratory conditions with very limited exposure to external influences. In contrast, white mountain sheep are kept on pasture prior to surgery and experienced various contacts with humans and wild animals. In addition, adenoviral infections are reported to be very common in sheep. 36 The former contact of the sheep to adenoviruses might have increased the inflammatory response against the viral vector inducing the retardation in bone formation. Moreover, this study shows that results from small animal experiments cannot simply be transferred to large animals.
Antibodies against the human BMP-2 were detected using an ELISA assay. Owing to the lack of commercially available ovine reagents no positive control was used in this assay and results within one preparation were compared only. The peak levels of anti-BMP-antibodies were found at 3 weeks after application of foreign BMP. 37 Although studies have shown, that recombinant hBMP-2 increases bone formation in sheep, thus favoring spinal fusion or tibial fracture healing, [38] [39] [40] [41] the occurrence of antibodies against a foreign BMP was also described in sheep leading to impaired mechanical properties of tibial repair after 16 weeks. 42 Ovine and human BMP-2 are more than 90% homologous. We propose that antibodies against hBMP-2 might be able to bind to ovine BMP-2 and influence the effect of endogenous BMP-2 and therefore inhibit the bone formation systemically. Although the presence of anti-BMP antibody would not necessarily delay bone healing, this observation could explain the inhibition of osteogenesis in the contralateral iliac crest defect after local application of Ad.BMP-2. No significant change was observed in the bone mineral density of cancellous bone at the distal radius (data not shown) indicating that the systemic inhibitory effect on osteogenesis did not affect normal, non-healing bone.
The dose of vector used in these experiments was based on prior studies by Baltzer et al., 20 who successfully used 2 Â 10 10 particles of Ad.BMP-2 in a rabbit model. The larger body size of a sheep and the increasing protein concentration of rhBMP-2 necessary to induce bone formation in these animals 10 guided our selection of 1 Â 10 11 particles of Ad.BMP-2 as the dose used in the present investigation. This dose induced high levels of marker gene expression, but appears to have triggered substantial immune and inflammatory responses that could be responsible for inhibiting osteogenesis both locally and systemically. Further investigations regarding the dose-response are needed. Ex vivo gene transfer offers one way to compensate for the immune response to the vector.
In conclusion, the results of this study indicate that although the dosage of 1 Â 10 11 particles of adenoviral vectors efficiently transfer genes to osseous defects in sheep, they inhibit bone formation even when a powerful osteogenic transgene is used. This, in turn, appears to reflect an immune response to the adenovirus and, in this case, a foreign transgene product. Further research is necessary to investigate the mechanism of inflammatory response and to determine the relevance of these findings to any eventual clinical application of these approaches in humans.
Materials and methods
Study design
The study involved two parts. The first part evaluated the efficacy of local adenoviral gene transfer. Group 1a consisted of 14 animals in which 1 Â 10 11 particles of Ad.Luc in 200 ml buffered saline solution were injected into the iliac crest defect as described below. Two animals each were killed at days 2, 7, 14, 21, 28, 35 and 42 after application of the viral vector to harvest tissue samples. The control group (group 1b) consisted of two sheeps, which received 200 ml of buffered saline solution. The control animals were killed at day 2. Tissue samples were harvested for luciferase activity as mentioned below and the draining lymph nodes examined during autopsy.
Part two of this study analyzed the effect of local Ad.BMP-2 administration on bone defect healing using a standardized iliac crest defect model as well as the effect on fracture healing using a standardized midshaft tibial osteotomy. In group 2a (n ¼ 6) Ad.BMP-2 was unilaterally injected during surgery into one iliac crest defect and osteotomy gap with 1 Â 10 11 particles in 200 ml buffered saline solution each. Group 2 (n ¼ 6) served as a control and was treated with 200 ml buffered saline solution without any virus. The contralateral iliac crest defect in all animals remained untreated. The bilateral approach offers the evaluation of a systemic effect. Callus formation was monitored by conventional X-ray at weekly intervals. Venous blood samples were taken prior to, and 14, 28 and 56 days after surgery. After 8 weeks all animals of groups 2a and 2b were killed under anesthesia and the right and left iliac crests were harvested for micro-CT and histological analysis. Both tibiae were harvested for mechanical testing and histological analysis. The study design was approved by the Swiss Ethical Committee for animal experiments.
Animal model
For this study adult female white mountain sheep (3-5 years of age, mean 3.8. years) were used. The monocortical iliac crest defect (depth 20 mm, diameter 5 mm)
Ad.BMP-2 and bone healing in sheep M Egermann et al was surgically created under general anesthesia using isoflurane and sterile conditions. Throughout the drilling procedure using a standard trephine drill, the region was irrigated with 0.9% saline solution and bone debris was removed. The osseous defect, surrounded by trabecular bone, was filled with gauze swabs for 3 min to stop bleeding and the viral vectors were directly injected into one defect. The contralateral defect remained untreated. In part two of the study an additional midshaft osteotomy of the right tibia stabilized by external fixator was created to investigate fracture healing as recently described in detail. 30 After unilateral application of the vector or saline solution the overlaying fascia and dermal layers were closed meticulously producing a closed chamber. The exposure was further closed in layers, a sterile dressing was applied. All animals received routine analgesic medication in the immediate post-operative period. No antibiotics were administered at any time during the experiment. The body weight was measured at weekly intervals.
Adenoviral vector
Recombinant, first generation (DE1, DE3) serotype 5 adenoviral vectors encoding bone morphogenetic protein-2 (Ad.BMP-2), the reporter gene firefly luciferase (Ad.Luc) and the green fluorescence protein gene (Ad.GFP) were used in this study. The human cytomegalovirus early promoter was used to drive gene expression. The recombinant viruses were propagated in the permissive cell line 293 and purified by standard cesium chloride banding techniques. Viral titers were determined by optical density at 260 nm (1 U ¼ 10 12 virions/ml). The vectors were stored until use at a concentration of 7 Â 10 12 particles/ml at À801C. Part one of this study made use of the reporter gene firefly luciferase (Ad.Luc) to analyze the efficiency of gene transfer. Adenoviral vectors encoding bone morphogenetic protein-2 was applied in part two to stimulate bone defect healing and fracture repair. Prior to the surgical procedure the Ad.BMP-2 was tested in vitro using primary cultures of ovine osteoblasts (50 000 cells). High levels (mean 148.7 ng/ml) of hBMP-2 were found in the supernatant 48 h after transduction and a significant increase of alkaline phosphatase (14-fold increase) could be demonstrated 4 days after transduction. Ad.GFP was used in vitro for detection of neutralizing antibodies as mentioned below.
Luciferase activity
For testing of luciferase activity in part one of this study standardized tissue samples from the injection site and from distant organs were taken from each animal following euthanasia. Three samples were taken from the injection site within o2 cm of distance including (1) trabecular bone, (2) the surrounding soft and (3) muscle tissue. Tissue samples from distant organs were taken from (1) trabecular bone from contralateral iliac crest, (2) quadriceps muscle of the right thigh, (3) right and left iliac lymph nodes as draining site from the iliac crest, (4) central and peripheral parts of the liver, (5) central and peripheral parts of the left kidney, (6) spleen, (7) central and peripheral parts of the left lung, (8) heart, (9) brain, (10) thyroid gland and (11) ovaries including the uterus. Samples (8 Â 8 Â 8 mm 3 ) were frozen in liquid nitrogen and stored at À801C until measurement of luciferase activity. The samples were homogenized using a sterile mortar and, after addition of 0.1 ml of saline solution, frozen to À801C and thawed three times in order to lyse the cells. After final thawing the samples were centrifuged at 10 000 r.p.m. for 5 min and the supernatant was retained for determination of luciferase activity. The luciferase activity of 100 ml of supernatant was measured in duplicate using a Luminometer LB9507 (EG&G Berthold Inc., Germany) according to the instructions of the manufacturer. The total protein content was analyzed in the supernatant by the Bradford method using the Bio-Rad Protein Assay (Bio-Rad Laboratories Inc., Hercules, CA, USA). All luciferase expression data were normalized to the amount of total protein present in the sample (relative light units/mg protein).
Radiographic evaluation
Bi-plane radiographs of the osteotomized tibia were taken immediately after surgery to exclude intra-operative bone pathologies and to ensure the correct placement of the external fixator. Lateral radiographs were repeated in weekly intervals. Prior to taking radiographs all animals were sedated (Domosedan s ) to avoid motion artifacts and the tibia including the external fixator was fixed to a custom made device to standardize the position of the tibia. The width of mineralized callus was determined and set in relation to baseline values.
Biomechanical testing
Immediately after killing both tibiae were dissected, cleaned of soft tissues (without affecting the soft and hard callus), and wrapped in 0.9% NaCl-soaked gauze. After the fixator bar was removed, torsional testing was performed at room temperature as described recently. 30 The force to failure in torsion and stiffness were measured from load-displacement curves. The values for osteotomized and intact tibiae of each animal were compared to obtain a ratio (osteomized/intact tibia) presented as percentages. The mean values of the ratio were calculated to analyze differences between the groups.
Micro-computed tomography measurement
For testing of newly formed bone within the defect at the iliac crests, including the defect at the center of the sample, were harvested. Bone structural parameters of these samples were determined using the micro-CT 20 (Scanco Medical, Bassersdorf, Switzerland) with a spatial resolution of 28 mm as described recently. 43 For all samples the volumes of interest were strictly limited to the initial size of the defect (diameter 5.0 mm). Bone volume/total volume was determined within the defect.
Histological analysis
Following CT the iliac crest samples were fixed in ethanol and embedded in methacrylate. The sample was cut parallel to the long axis of the defect (Leitz 1600 saw microtome, Leica, Switzerland) and ground (Exact Micro Grinding System, Exact, Germany) to produce three undecalcified sections of 80-100 mm thickness. The sections were stained with Giemsa-eosine (Fluka 48900 and Fluka 45240, Fluka, Switzerland).
For evaluation of newly formed bone within the defect macroradiographs (Faxitron 804, Faxitron X-ray Corporation, Wheeling, IL, USA, Schweizer AG, Zü rich)
Ad.BMP-2 and bone healing in sheep M Egermann et al were taken of each section and subsequently digitized into the Zeiss Axio Vision 3.0 software (Carl Zeiss Vision, Munich, Germany). In order to analyze the area of newly formed bone the defect was framed, a standardized threshold was set over grayscales to define all areas of mineralized tissue and finally all areas were summed and set in proportion to the original defect. For quantitative analysis of the inflammatory cells within the defect first all sections were stained with Giemsaeosine (Fluka 48900 and Fluka 45240, Fluka, Switzerland). Using a magnification of Â 20 with an imaging microscope (Zeiss Axioplan) six representative pictures where captured and a red filter was inserted to increase contrast. The number of inflammatory cells was analyzed using a semiautomated method at Zeiss KS 400 imageanalysis system. The region of interest was framed and using a defined threshold all areas were selected with the same gray scale as the target cells. Within these areas all target cells were characterized in the next step by size (12-20 mm) and unique round shape. The cell number was set in proportion to the evaluated area.
Detection of antibody
Venous blood samples were taken from each animal before surgery and at days 14, 28 and 56 after application of the viral vector. The blood was centrifuged and the serum stored at À201C. Anti-Ad5-neutralizing antibody titers were measured by the ability of serum to prevent infection of HeLa cells (a human epithelial cell line) by Ad5.GFP. The HeLa cells were cultured in Dulbecco'smodified Eagle medium (DMEM) containing 10 ml/l penicillin, 2 ml/l fungizone and 3 ml/l gentamicin. Cells were seeded into 48-well plates (Falcon 3078; Becton Dickinson Biosciences, San Jose, CA, USA) at a density of 5 Â 10 4 cells/well in 500 ml of medium. In all, 1 Â 10 6 particles of Ad-GFP were pre-incubated with serial dilutions of serum samples (1:25, 1:50, 1:100, 1:200 and 1:400) in DMEM for 1 h at 41C. Thereafter, the HeLa cells were incubated with the serum-vector mix for 48 h at 371C. The expression of GFP was evaluated by fluorescence microscopy (excitation l ¼ 460 nm, emittission l ¼ 510 nm). The neutralizing antibody titer was defined as the dilution of serum that led to o50% GFP expression level compared to HeLa cells infected with 1 Â 10 6 particles of Ad.GFP without addition of diluted serum. All assays were performed in duplicate. For technical reasons, the lowest dilution tested was 1:25 and the highest dilution tested was 1:400.
An indirect ELISA was performed to determine whether antibody against human BMP had developed in the sheep (Figure 1) . A microtiter plate with 96 wells (Costar 3590, Corning Inc., Acton, MA, USA) was coated with recombinant human BMP-2 (0.1 mg/well) (355-BM-010, R&D systems Europe Ltd, Oxon, UK) diluted in bicarbonate/carbonate buffer at pH 9.6 at 41C overnight. Uncoated sites were blocked with 1% bovine serum albumin in phosphate-buffered saline (PBS). The plates were washed using PBS+0.05% Tween-20 and then incubated with sheep serum in serial dilutions (1:10, 1:100 and 1:1000) for 1 h at 371C. The sheep serum acted as a primary antibody in this assay. After washing away any unbound substances, an anti-sheep-immunoglobulin G peroxidase-conjugated antibody (Cat #A4315, SigmaAldrich, Buchs, Switzerland, diluted 1:1000) was added to the wells as a secondary antibody and incubated at 371C for 1 h. Following a wash to remove any unbound antibody-enzyme reagent, a peroxidase substrate solution (Cat #T0440, Sigma, USA) was added (50 ml/well) and the color reaction was stopped after 20 min with the addition of 2.5 M H 2 SO 4 (50 ml/well). A yellow end product developed in proportion to the amount of ovine anti-hBMP2 antibody in the serum samples and was then read at a wavelength of 450 nm (Perkin-Elmer, Fremont, CA, USA). Since no standards were available, the concentration of the antibody could not be calculated from the absorbance measured. Therefore, only comparisons of absorbance values within the same plate were allowed for evaluation.
Statistical analysis
Statistical analysis was performed using SPSS software package (SPSS Inc., Chicago, USA). Results are presented in mean7s.d. if not otherwise stated. Non-parametric tests (Mann-Whitney test) were used when appropriate for comparison between the groups. The level of significance was set at 0.05.
